NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition

Oncogenesis

Volumn 2, Issue , 2013, Pages

  Osborne, J K ^a   Larsen, J E ^b   Gonzales, J X ^a   Shames, D S ^b,d   Sato, M ^b,e   Wistuba, I I ^c   Girard, L ^a,b   Minna, J D ^a,b   Cobb, M H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d GENENTECH INC   (United States)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

migration; NeuroD1; neuroendocrine; TrkB

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; MESSENGER RNA; NERVE CELL ADHESION MOLECULE; NEUROGENIC DIFFERENTIATION FACTOR; PROTEIN P53; SYNAPTOPHYSIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL DIFFERENTIATION; CELL INVASION; CELL LINEAGE; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM;

EID: 84883202463     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.24     Document Type: Article

References (43)

1. Borges M, Linnoila RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997; 386: 852-855. (Pubitemid 27181261)
2. Cindolo L, Franco R, Cantile M, Schiavo G, Liguori G, Chiodini P et al. NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension? Eur Urol 2007; 52: 1365-1373. (Pubitemid 47454669)
3. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol 2006; 19: 1358-1368. (Pubitemid 44423084)
4. Rostomily RC, Bermingham-McDonogh O, Berger MS, Tapscott SJ, Reh TA, Olson JM. Expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res 1997; 57: 3526-3531. (Pubitemid 27355503)
5. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol 1997; 28: 1373-1378. (Pubitemid 28013632)
6. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34: 300-313.
7. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39: 707-712.
8. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135-148.
9. Cantile M, Kisslinger A, Cindolo L, Schiavo G, D'Anto V, Franco R et al. cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers. J Cell Physiol 2005; 205: 202-210. (Pubitemid 41428902)
10. Eyden B, Moss J, Shore I, Banerjee SS. Metastatic small cell malignant melanoma: a case requiring immunoelectronmicroscopy for the demonstration of latticedeficient melanosomes. Ultrastruct Pathol 2005; 29: 71-78. (Pubitemid 40389527)
11. Eyden B, Pandit D, Banerjee SS. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases. Histopathology 2005; 47: 402-409. (Pubitemid 41428489)
12. Pilozzi E, Cacchi C, Di Napoli A, Pini B, Duranti E, D'Andrilli A et al. Primary malignant tumour of the lung with neuroendocrine and melanoma differentiation. Virchows Arch 2011; 459: 239-243.
13. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754-764.
14. Syder AJ, Karam SM, Mills JC, Ippolito JE, Ansari HR, Farook V et al. A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype. Proc Natl Acad Sci USA 2004; 101: 4471-4476. (Pubitemid 38437435)
15. Osborne JK, Larsen JE, Shields MD, Gonzales JX, Shames DS, Sato M et al. NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM. Proc Natl Acad Sci USA 2013; 110: 6524-6529.
16. Banerjee SS, Eyden B. Divergent differentiation in malignant melanomas: a review. Histopathology 2008; 52: 119-129.
17. Bhat KM, Maddodi N, Shashikant C, Setaluri V. Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling. Nucleic Acids Res 2006; 34: 3819-3832. (Pubitemid 44400431)
18. Maddodi N, Bhat KM, Devi S, Zhang SC, Setaluri V. Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. J Biol Chem 2010; 285: 242-254.
19. Cuomo M, Nicotra MR, Apollonj C, Fraioli R, Giacomini P, Natali PG. Production and characterization of the murine monoclonal antibody 2G10 to a human T4-tyrosinase epitope. J Invest Dermatol 1991; 96: 446-451.
20. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 2007; 5: 6.
21. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009; 4: e4563.
22. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8: 2079-2085.
23. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L et al. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 2009; 33: 237-247.
24. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004; 64: 9027-9034. (Pubitemid 39665513)
25. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006; 66: 2116-2128.
26. Sato M, Larsen JE, Lee W, Sun H, Shames DS, Dalvi MP et al. Human Lung Epithelial Cells Progressed to Malignancy through Specific Oncogenic Manipulations Mol Cancer Res 2013; 11: 638-650.
27. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010; 468: 572-575.
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
29. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74: 813-822. (Pubitemid 23270601)
30. Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005; 125: 1242-1251.
31. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39(Database issue): D945-D950.
32. Haapajarvi T, Pitkanen K, Laiho M. Human melanoma cell line UV responses show independency of p53 function. Cell Growth Differ 1999; 10: 163-171. (Pubitemid 29138523)
33. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-263.
34. Liu Y, Encinas M, Comella JX, Aldea M, Gallego C. Basic helix-loop-helix proteins bind to TrkB and p21(Cip1) promoters linking differentiation and cell cycle arrest in neuroblastoma cells. Mol Cell Biol 2004; 24: 2662-2672. (Pubitemid 38381259)
35. Gupta A, Wang Y, Browne C, Kim S, Case T, Paul M et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 2008; 68: 50-60.
36. Huang P, Kishida S, Cao D, Murakami-Tonami Y, Mu P, Nakaguro M et al. The neuronal differentiation factor NeuroD1 downregulates the neuronal repellent factor Slit2 expression and promotes cell motility and tumor formation of neuroblastoma. Cancer Res 2011; 71: 2938-2948.
37. Adameyko I, Lallemend F, Aquino JB, Pereira JA, Topilko P, Muller T et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 2009; 139: 366-379.
38. Pavan WJ, Raible DW. Specification of neural crest into sensory neuron and melanocyte lineages. Dev Biol 2012; 366: 55-63.
39. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. p53 suppresses the self-renewal of adult neural stem cells. Development 2006; 133: 363-369. (Pubitemid 43210724)
40. Gao Z, Ure K, Ables JL, Lagace DC, Nave KA, Goebbels S et al. Neurod1 is essential for the survival and maturation of adult-born neurons. Nat Neurosci 2009; 12: 1090-1092.
41. Ninkina N, Grashchuck M, Buchman VL, Davies AM. TrkB variants with deletions in the leucine-rich motifs of the extracellular domain. J Biol Chem 1997; 272: 13019-13025. (Pubitemid 27216721)
42. Lawrence MC, McGlynn K, Park BH, Cobb MH. ERK1/2-dependent activation of transcription factors required for acute and chronic effects of glucose on the insulin gene promoter. J Biol Chem 2005; 280: 26751-26759. (Pubitemid 41040708)
43. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB et al. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res 2003; 63: 2905-2912. (Pubitemid 36667163)